RedHill Biopharma Ltd. announced that the U.S. FDA has accepted for review the New Drug Application (NDA) for Talicia (RHB-105)1 for H. pylori infection. The NDA for Talicia has also been granted Priority Review designation and was assigned a target Prescription Drug User Act (PDUFA) action date by the FDA of November 2, 2019.
Commercial launch of Talicia with RedHill’s existing U.S. sales force is planned shortly following potential FDA approval. If approved, Talicia would be eligible for a total of eight years of U.S. market exclusivity.
“The efficacy of current standard-of-care therapies for H. pylori bacterial infection continues to decline due to the high and steadily increasing prevalence of antibiotic-resistant strains. This public health concern is widely recognized by the U.S. government and other leading health agencies, including the World Health Organization, which classified H. pylori as a Group I carcinogen and highlighted the urgent need for new treatments for H. pylori eradication,” said Dror Ben-Asher, Chief Executive Officer of RedHill Biopharma. “The acceptance for review of the NDA for Talicia and the Priority Review designation are encouraging steps as we continue our intensive preparations for a potential U.S. commercial launch of Talicia as a new first-line, standard-of-care therapy for H. pylori. We continue to work closely with the FDA, with the aim of bringing this important new therapy to patients.”
Breaking News
FDA Accepts RedHill Biopharma’s NDA for Talicia
Commercial launch of H. pylori treatment is planned shortly following potential FDA approval
07.16.19
Related Breaking News
-
Bio News | Breaking News | Industry News
High Purity New England Bolsters Biopharma Solutions Services
Launches customizable cell culture bioreactor line.Tim Wright, Editor, Contract Pharma 02.25.21
-
Biologics, Proteins, Vaccines | Breaking News | Collaborations & Alliances | Industry News
AMRI Contributes to Efforts to Increase COVID-19 Vax Supply
Joins network of approved manufacturers of lipid excipients for Pfizer-BioNTech COVID-19 vaccine.Tim Wright, Editor, Contract Pharma 02.25.21
-
Analytical Services | Breaking News | Drug Discovery | Facilities | Industry News | R&D
CatSci Opens New Site in UK
Strengthens analytical capabilities with the opening of a secondary site in Dagenham backed by a $4.2 million investment.Tim Wright, Editor, Contract Pharma 02.25.21
-
Breaking News | Collaborations & Alliances | Drug Development | Industry News | Solid Dosage/Creams/Ointments
Pfizer Partners with Medicines Manufacturing Innovation Center
To transform the formulation of oral solid dosage medicines.Tim Wright, Editor, Contract Pharma 02.25.21
-
Breaking News | Industry News | Packaging & Tracking | Serialization
Covectra Introduces Next-Gen Serialization Solution
StellaGuard smart label and mobile authentication solution combats counterfeiting of products.Tim Wright, Editor, Contract Pharma 02.25.21
-
Breaking News | Collaborations & Alliances | Drug Discovery | Industry News | Information Technology
CrownBio & JSR Life Sciences Partner with Cambridge Quantum Computing
Will leverage quantum machine learning for novel cancer treatment biomarker discovery.Tim Wright, Editor, Contract Pharma 02.25.21
-
APIs | Breaking News | Industry News
C2 Pharma Completes Multiple Regulatory Filings
Expands API portfolio to solidify position as a leading ophthalmic API supplier to the pharmaceutical industry.Tim Wright, Editor, Contract Pharma 02.25.21
-
Breaking News | Industry News | Information Technology
Stevanato Group Launches AI Platform
To further enhance detection performance of its visual inspection machines.Tim Wright, Editor, Contract Pharma 02.25.21
-
Analytical Services | Breaking News | Facilities | Industry News | Vials
Bormioli Opens New Glass Research Center
The international producer of containers for pharmaceutical use has signed a five-year agreement with IMEM-CNR to promote materials research.Tim Wright, Editor, Contract Pharma 02.25.21
-
Bioanalytical Services | Breaking News | Industry News | Preclinical Outsourcing
Altasciences Contributes to Vibegron Approval
Provided clinical support for two drug-drug interaction studies and a bioavailability trial for the overactive bladder treatment.Kristin Brooks 02.24.21
-
Breaking News | Drug Development | Industry News
Cyprium, Sentynl Therapeutics Ink Asset Purchase Agreement
Sentynl acquires CUTX-101 Copper Histidinate for the treatment of Menkes disease for $20 million in upfront and regulatory milestones.Kristin Brooks 02.24.21
-
Biologics, Proteins, Vaccines | Breaking News | Drug Development | Industry News | Information Technology
Pfizer Selects Seven Bridges to Support RNA Sequencing Data
Seven Bridges will centralize and manage terabytes scRNASeq data, which provides detailed analysis of gene expression in individual cells.Kristin Brooks 02.24.21
-
Analytical Services | Breaking News | Facilities | Industry News | Laboratory Testing
ACG Launches ACG Laboratories
Opens a process development lab in Shirwal, India.Tim Wright, Editor, Contract Pharma 02.23.21
-
Breaking News | Collaborations & Alliances | Industry News | Solid Dosage/Creams/Ointments
Glatt and Aprecia Enter 3D-Printing Collaboration
Aprecia's compression-free 3DP manufacturing platform expands Glatt capabilities in innovative particle design.Tim Wright, Editor, Contract Pharma 02.23.21
-
Bio News | Biologics, Proteins, Vaccines | Breaking News | Collaborations & Alliances | Facilities | Industry News
Catalent Acquires Delphi Genetics
Launches US plasmid manufacturing site to establish global pDNA development and manufacturing capabilities.Tim Wright, Editor, Contract Pharma 02.23.21
